Inito Raises $29 Million to Expand At-Home Health Tests
- Inito secures $29 Million in Series B led by Bertelsmann India
- Funding to expand from fertility to broader health diagnostics
- Startup focuses on AI-driven synthetic antibody tests
At-home diagnostics startup Inito has raised $29 million in a Series B round, led by Bertelsmann India Investments with participation from existing investor Fireside Ventures. This brings the company’s total funding to $45 million since its launch.
Founded in 2021, Inito started with an at-home fertility device that measures four key hormone markers. The device uses proprietary models to interpret results and has already processed over 30 million data points worldwide.
With this new funding, the startup plans to expand beyond fertility testing into broader hormone and general health diagnostics. The company is leveraging AI-enabled antibody engineering to build synthetic antibodies, moving away from traditional methods that rely on animals and manual screening. This approach aims to make at-home diagnostic tests more stable, reliable, and accessible, eliminating the need for complex clinical infrastructure.
Also Read: Toffee Coffee Roasters Raises Rs 5 Crore in Pre-Series A Round
Co-founders Aayush Rai and Varun AV said the next phase includes developing tests for testosterone, thyroid, vitamins, and other health markers. Inito already holds over 20 patents related to its testing platform and operates teams in Bengaluru, Dubai, and London.
The Series B funding will help Inito scale its AI-driven diagnostics, making advanced health monitoring easy to perform at home and opening doors for personalized, data-backed healthcare for women and general health users.
